去年2月，天合光能(688599.SH)因专利问题，向阿特斯(688472.SH)发起索赔，要求后者赔偿10.58亿 元，目前该事项未能查到最终公开结果。 截至去年三季度末，爱旭股份货币资金48.45亿元，负债总额288.45亿元。资产负债率77.6%，较6月底 的85.75%下滑约8个百分点。 智通财经记者｜马悦然 爱旭股份预计去年亏损12亿-19亿元，同比减亏。该公司在公告中透露，2025年ABC组件销售量同比实 现翻倍以上增长；报告期内经营性现金流、制造成本、组件销售毛利率、资产减值同比均有明显改善。 为取得TCL中环(002129.SZ)旗下Maxeon的BC专利授权，爱旭股份和隆基绿能(601012.SH)曾就 TOPCon、BC技术在全球多地产生专利纠纷；晶澳科技(002459.SZ)和正泰新能就TOPCon技术问题闹上 法庭等。 根据最新业绩预告，TCL中环预计2025年亏损82亿-96亿元，较上年同期98.18亿元的亏损有所改善。 ...

Core Viewpoint - The patent dispute between Rongbai Technology and LG Chem is still in the confrontation stage, and a clear outcome is unlikely in the short term [2][5]. Summary by Sections Patent Dispute Overview - Rongbai Technology and LG Chem are involved in a patent dispute, with LG Chem filing for an injunction in a South Korean court to block the production and circulation of allegedly infringing products [3]. - Rongbai Technology asserts that all products involved do not infringe on any LG Chem patents, and there have been no judgments or rulings confirming any infringement [3][4]. Legal Proceedings - LG Chem has filed a lawsuit against Rongbai Technology's subsidiary, Zai Shi Energy, claiming infringement of five Korean patents related to the preparation of cathode materials [3]. - The South Korean court has not yet made any rulings, and the case is still under normal review, indicating no urgent situation exists [4]. Temporary Injunction Conditions - For a temporary injunction to be effective under South Korean law, three conditions must be met: urgency of the case, a high likelihood of winning, and potential for irreparable harm to the rights holder [3]. - Rongbai Technology's legal representatives believe that the likelihood of the temporary injunction being granted is low under normal circumstances [4]. Patent Validity and Challenges - Rongbai Technology has successfully invalidated one of the five patents in question and plans to appeal the judgment regarding the remaining patents [4]. - The patents involved have ambiguous protection boundaries and may be covered by earlier inventions, which could weaken LG Chem's claims [4]. Implications for Industry - The patent conflict reflects the risks faced by Chinese companies expanding overseas and highlights significant challenges in the global advancement of the new energy industry [5].

Core Viewpoint - The U.S. Supreme Court's decision to hear a patent dispute involving Amarin Pharma's cardiovascular drug Vascepa may significantly impact generic drug manufacturers and the "skinny label" strategy [1] Group 1: Patent Dispute - The case centers around Amarin Pharma's Vascepa, which is a cardiovascular drug [1] - The outcome of this dispute could set a precedent affecting the generic drug market [1] Group 2: Implications for Generic Drug Makers - The ruling may influence how generic drug makers approach the development and marketing of their products [1] - The "skinny label" strategy, which allows generics to avoid patent infringement by omitting certain indications, could be affected by the court's decision [1]

Core Viewpoint - New Ning Logistics' subsidiary has filed a lawsuit against Zhuhai Guanyu, seeking compensation of 64.52 million yuan for losses incurred from a fire incident [1][2]. Group 1: Lawsuit Details - The fire incident occurred in December 2015, with the court ruling that Zhuhai Guanyu is 30% responsible for the damages due to lithium batteries stored at the fire site [2]. - The total compensation and litigation costs determined by the Supreme People's Court amount to 215 million yuan, with New Ning Logistics claiming 30% from Zhuhai Guanyu [2]. - The lawsuit requests Zhuhai Guanyu to pay 64.52 million yuan plus interest, which is estimated at 1.967 million yuan until October 15, 2025 [2]. Group 2: Financial Performance - For the first three quarters of 2025, New Ning Logistics reported total revenue of 391 million yuan, a year-on-year increase of 6.68%, but a net loss of 5.06 million yuan [3]. - The company has experienced continuous losses for seven years, with the latest annual report indicating a net loss of 72.76 million yuan for 2024 [4][5]. - The total undisclosed litigation and arbitration amounts to approximately 12.53 million yuan, representing 6.24% of the company's latest audited net assets [2]. Group 3: Zhuhai Guanyu's Situation - Zhuhai Guanyu is a major supplier of consumer batteries and is also expanding into power and energy storage batteries [5]. - The company is currently involved in a patent lawsuit with Ningde New Energy Technology Co., facing a judgment to pay 9.90 million yuan and stop manufacturing certain battery models [6]. - As of the latest updates, several of ATL's patents have been declared invalid, and multiple lawsuits have been withdrawn or dismissed [6].

Core Viewpoint - The European Unified Patent Court (UPC) ruled that Ecovacs' request for an ex-parte order against Roborock during the IFA event was unlawful and subsequently revoked the order, highlighting the misuse of the UPC's emergency protection mechanism [1][4][13]. Group 1: Event Background - Ecovacs and Roborock are prominent domestic vacuum cleaner companies that have gained significant market share in Europe in recent years [4]. - During the IFA 2025, Ecovacs claimed that Roborock infringed its EP3808512 patent and sought evidence preservation from the UPC [10]. - The UPC is a supranational court established to address patent litigation across EU member states, providing jurisdiction that surpasses national courts [4]. Group 2: Legal Mechanism - An ex-parte order allows the court to issue orders without hearing the defendant's side, aimed at protecting urgent patent infringement cases [6][7]. - The UPC's emergency measures are designed to prevent the loss of critical evidence that may occur if immediate action is not taken [8][9]. Group 3: Court's Ruling - The UPC determined that Ecovacs' application for the ex-parte order was based on misleading and incomplete factual statements, violating the UPC's procedural rules [15][18]. - The court emphasized that if the facts had been fully disclosed, the ex-parte order would not have been issued, indicating a lack of urgency in the case [19][20]. Group 4: Principles of Ex-Parte Orders - The UPC operates under four key principles for issuing ex-parte orders: truthful representation, urgency, necessity, and proportionality [21][28]. - Ecovacs failed to demonstrate urgency as Roborock's products were already available for purchase on platforms like Amazon, undermining the claim of immediate need for evidence preservation [25][26]. Group 5: Industry Implications - The incident reflects the competitive nature of the cleaning appliance industry, where companies may leverage patent disputes to gain market advantages [35][40]. - The outcome of patent disputes can significantly impact market access, as seen when Roborock successfully sought a sales ban on Ecovacs' products in Germany [40].

Core Viewpoint - The company, Shunluo Electronics, has filed a lawsuit against Murata Manufacturing Co., Ltd. for maliciously initiating a patent infringement lawsuit, which has been accepted by the Shanghai Intellectual Property Court [1][3] Group 1: Lawsuit Details - Shunluo Electronics has made four specific requests in the lawsuit: 1. To confirm that Murata's previous patent infringement lawsuit constitutes malicious litigation 2. To seek compensation for economic losses amounting to 1.5 million RMB 3. To require Murata to publicly apologize in Chinese, Japanese, and English on its official website and designated media to mitigate the impact 4. To have Murata bear the litigation costs [3] Group 2: Company Position - The company asserts that Murata's prior lawsuit lacks a legitimate basis or shows clear malice, forcing Shunluo Electronics to allocate resources to respond, thus prompting this counter-suit to protect its legal rights [3] - The company emphasizes that the ongoing case has not yet gone to trial, making it impossible to accurately predict its impact on profits, with the final outcome dependent on the court's ruling [3] - The lawsuit is characterized as a legitimate measure to counter suspected malicious litigation and will not affect the company's normal production and operations [3] Group 3: Industry Implications - This counter-suit signifies an escalation of the previous patent infringement dispute initiated by Murata, with the court's recognition of "malicious litigation" expected to be a focal point of industry attention [3]

Core Viewpoint - Whirlpool has filed a complaint with the U.S. International Trade Commission (ITC) to block the import and sale of microwaves produced by competitors such as Samsung and LG, claiming these products infringe on its patented technology [1] Group 1: Company Actions - Whirlpool is seeking to protect its market by alleging that its competitors have copied its patented technology related to low-profile microwave hood combination products (LP-MHC) [1] - The company asserts that it was the sole supplier of LP-MHC products in the U.S. before the alleged infringement began [1] Group 2: Competitors - The complaint specifically targets South Korean competitors Samsung and LG for infringing on five of Whirlpool's patents [1] - Whirlpool emphasizes its role in creating the LP-MHC product category, highlighting its innovation in this market segment [1]

Core Points - The U.S. International Trade Commission has initiated a new investigation to determine whether the import of Apple's latest smartwatch should be banned due to a patent dispute with Masimo Corporation [1] - The investigation will assess if Apple's smartwatch infringes on Masimo's patents related to blood oxygen measurement technology, with a decision expected within six months [1] - Apple claims the lawsuit is baseless and aims to hinder the launch of its blood oxygen detection feature, alleging that Masimo is attempting to copy Apple's smartwatch design [1] Group 1 - A federal jury in California recently ruled that Apple infringed on a Masimo patent, awarding Masimo $634 million in damages [1] - In 2023, the Commission prohibited the import of Apple's Series 9 and Ultra 2 smartwatches after finding that Masimo's patents were infringed, leading Apple to remove the blood oxygen detection technology from its devices to avoid the ban [1] - In August, Apple updated the blood oxygen feature for certain Apple Watch models after receiving approval from U.S. Customs and Border Protection, despite Masimo's lawsuit against the agency [2] Group 2 - A California judge declared Masimo's trade secret case against Apple as "invalid" due to a hung jury [2] - Last year, Apple won a minor victory in Delaware, receiving $250 in a counterclaim against Masimo, which was accused of infringing on two of Apple's design patents [2]

Core Points - A California federal jury ruled that Apple infringed on Masimo's patents related to blood oxygen detection technology in the Apple Watch, ordering Apple to pay approximately $634 million in damages [1][3] - Apple plans to appeal the ruling, while Masimo views the decision as a significant victory for protecting its innovations and intellectual property [1] Legal Disputes - The ruling is part of a long-standing patent dispute, with Masimo previously accusing Apple of poaching key employees and misappropriating pulse oximetry technology for the Apple Watch [3] - In 2023, the U.S. International Trade Commission (ITC) found Apple guilty of infringement, leading to an import ban on the Apple Watch Series 9 and Ultra 2 [3] - To comply with the import ban, Apple temporarily removed the blood oxygen detection feature from its products until a revised version was approved by U.S. Customs and Border Protection in August [3] Ongoing Legal Proceedings - The ITC announced it will initiate a new process to review whether the updated Apple Watch still falls under the import ban [3] - Masimo's lawsuit regarding the customs approval decision is still pending, and Apple has appealed the previous import ban to the federal appeals court [3] - The companies have engaged in multiple legal battles, including a failed commercial secrets lawsuit in California in 2023 and a symbolic $250 judgment in Delaware in 2024 favoring Apple [3]

Core Viewpoint - The U.S. International Trade Commission has initiated a new proceeding to assess whether imports of Apple's updated Apple Watches should be banned due to a patent dispute with a medical technology company [1] Group 1: Legal Proceedings - The decision to hold a new proceeding indicates ongoing legal challenges faced by Apple in relation to its product imports [1] - The patent dispute highlights the competitive landscape in the technology and medical sectors, where intellectual property rights are increasingly contested [1] Group 2: Market Implications - A potential ban on Apple Watch imports could significantly impact Apple's market presence and sales in the wearables segment [1] - The outcome of this proceeding may set a precedent for future patent disputes involving technology companies and their product lines [1]